Lucy Therapeutics Appoints Neuroscience Drug Discovery and Development Expert Christopher J. Winrow, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Lucy Therapeutics, Inc., a private biotech company developing proprietary mitochondrial-based small molecule therapies and biomarkers for neurological diseases, today announced the appointment of business-side biopharma leader Julia Gaebler, Ph.D., as Chief Business Officer. Dr. Gaebler has more than 25 years of business development and strategy experience in the life sciences industry, across biopharma, consulting, and academia.
Lucy Therapeutics Expands Leadership Team with Appointment of Julia Gaebler, Ph.D., as Chief Business Officer